Search company, investor...

Bluefish Pharmaceuticals


Other Investors | Alive

About Bluefish Pharmaceuticals

Bluefish Pharmaceuticals offers a range of quality pharmaceuticals at prices that as many as possible will be able to afford.

Headquarters Location

Riddargatan 16

114 51,


Missing: Bluefish Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Bluefish Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Bluefish Pharmaceuticals Patents

Bluefish Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Media servers, Videotelephony, Container formats, Multimedia, Wagering


Application Date


Grant Date



Related Topics

Media servers, Videotelephony, Container formats, Multimedia, Wagering



Latest Bluefish Pharmaceuticals News

Sweden: Ekman to replace Lindholm as CEO at Bluefish Pharmaceuticals

Dec 1, 2021

LaingBuisson News By Erik Ekman, CEO Bluefish Pharamceuticals Erik Ekman is to take on the role of CEO at Bluefish Pharmaceuticals during spring 2022 in the wake of Berit Lindholm, the current CEO, deciding to leave the company for a non-competitive organisation. Ekman currently holds the COO position in the company, a position he has held for the last four years. He previously… You must be a HMI Subscriber to view this content. Login » Nick Herbert has over 30 years’ experience in the financial markets, as both a practitioner and journalist. He started work as an investment banker in London, before joining International Financing Review (IFR) to report on debt capital markets and derivatives. He moved to Singapore in 2000 to manage IFR’s financial markets editorial team throughout Asia, before returning to London in 2009 to take up the position of Publisher for Reuters Capital Markets Publications. For the last five years he has been covering global capital markets, ESG finance and healthcare markets on a freelance basis.

Bluefish Pharmaceuticals Frequently Asked Questions (FAQ)

  • What is Bluefish Pharmaceuticals's latest funding round?

    Bluefish Pharmaceuticals's latest funding round is Other Investors.

  • Who are the investors of Bluefish Pharmaceuticals?

    Investors of Bluefish Pharmaceuticals include Catella Fondforvaltning, Thenberg funds, Coeli Sverige, Varenne Investment, Atlant Fonder and 4 more.

  • Who are Bluefish Pharmaceuticals's competitors?

    Competitors of Bluefish Pharmaceuticals include Somaxon Pharmaceuticals, ISTA Pharmaceuticals, Trubion Pharmaceuticals, Alinea Pharmaceuticals, Arriva Pharmaceuticals and 12 more.

Compare Bluefish Pharmaceuticals to Competitors

Greystone Pharmaceuticals

Greystone Pharmaceuticals is a healthcare company focused on wound technologies.

Ribozyme Pharmaceuticals

Ribozyme Pharmaceuticals offers RNA-based pharmaceuticals for human disease

Alinea Pharmaceuticals

Alinea Pharmaceuticals, Inc. offers pharmaceuticals for diabetes and related metabolic disorders

Ausio Pharmaceuticals

Ausio Pharmaceuticals is a company focused on the clinical development of S-Equol for major medical needs.

Zebra Pharmaceuticals

Zebra Pharmaceuticals offers customized health products through nature and science.

Arriva Pharmaceuticals

Arriva Pharmaceuticals, Inc. offers enzyme inhibitor replacement & therapy

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.